Global Oncology Biosimilars Market

Oncology Biosimilars Comprehensive Study by Type (G-CSF, Hematopoietic Agents, Monoclonal Antibodies), Application (Cancer Treatment Drugs, Supportive Care Drugs), Drug type (Monoclonal antibody (mAb), Immunomodulators, Hematopoietic agents, G-CSF, Others), Cancer type (Lung Cancer, Colorectal cancer, Cervical Cancer, Breast Cancer, Kidney cancer, Stomach cancer, Brain Cancer, Others), End user (Retail Pharmacies, Hospitals), Distribution channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) Players and Region - Global Market Outlook to 2027

Oncology Biosimilars Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
According to the World Health Organization (WHO), Cancer accounts for one in six deaths globally, claiming more lives than AIDS, tuberculosis, and malaria combined. This disease represents a big burden on the healthcare systems worldwide due to high-cost factor for treatment and therapeutics. The patent expiry of several cancer therapeutics has resulted in the entry of Biosimilars which are being incorporated in the treatment of oncology. Due to the high incidence of cancer, the market of Oncology Biosimilars is providing huge growth opportunity to the key vendors. According to the U.S. Food and Drug Administration (FDA), Biosimilars is a biological product that is highly similar to an existing, approved reference product and has no clinically meaningful differences. These are manufactured by different companies on being approved officially for cancer treatment. Oncologic Biosimilars are cost-effective molecules with the same efficacy and potency as original biologics.
This growth is primarily driven by Increased prevalence of cancer leading to demand for affordable therapies to treat cancer, Patent expiry of existing biologics and Increasing number of alliances for the development of Biosimilars..

Globally, a noticeable market trend is evident The number of FDA approved cancer therapies continues to rise, with 63 cancer drugs launching within the past five years . The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Biocon (India), Celltrion (South Korea), Dr Reddy laboratories (India), F Hoffman-La Roche (Switzerland), Mylan (United States), Sandoz (Germany), Teva Pharmaceuticals Ltd.(Israel), STADA Arzneimittel AG (Germany), Pfizer Inc. (United States), BIOCAD (United States) and Sanofi (France) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On June 4, 2018, the Food and Drug Administration approved Fulphila (pegfilgrastim-jmdb, Mylan GmbH) as a biosimilar to Neulasta (pegfilgrastim, Amgen, Inc.) which is not a cancer treatment but a supportive care medicine for cancer treatment.
Monoclonal antibodies are expected to grow at the highest growth rate in 2026 due to recent FDA approval of Mvasi (bevacizumab-awwb) and Ogviri (trastuzumab-dkst) in the United States and India is at the forefront in the emerging market with more approved Biosimilars then any other market in September 2018.

Market Drivers
  • Increased prevalence of cancer leading to demand for affordable therapies to treat cancer
  • Patent expiry of existing biologics
  • Increasing number of alliances for the development of Biosimilars.

Market Trend
  • The number of FDA approved cancer therapies continues to rise, with 63 cancer drugs launching within the past five years
  • Over one-third of trials are using biomarkers to stratify patients, pointing to even more personalized cancer treatments in the future.

Restraints
  • Adoption of Biosimilars by many oncologists due to high cost.

Opportunities
Patent expiry will provide an opportunity to the pharmaceutical companies to manufacture more Biosimilars leading to fuel the market.
Challenges
Potential of Biosimilars to mitigate rising health care cost while improving highly effective therapies.

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Oncology Biosimilars Study Sheds Light on
— The Oncology Biosimilars Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Oncology Biosimilars industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Oncology Biosimilars industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • G-CSF
  • Hematopoietic Agents
  • Monoclonal Antibodies
By Application
  • Cancer Treatment Drugs
  • Supportive Care Drugs
By Drug type
  • Monoclonal antibody (mAb)
  • Immunomodulators
  • Hematopoietic agents
  • G-CSF
  • Others

By Cancer type
  • Lung Cancer
  • Colorectal cancer
  • Cervical Cancer
  • Breast Cancer
  • Kidney cancer
  • Stomach cancer
  • Brain Cancer
  • Others

By End user
  • Retail Pharmacies
  • Hospitals

By Distribution channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased prevalence of cancer leading to demand for affordable therapies to treat cancer
      • 3.2.2. Patent expiry of existing biologics
      • 3.2.3. Increasing number of alliances for the development of Biosimilars.
    • 3.3. Market Challenges
      • 3.3.1. Potential of Biosimilars to mitigate rising health care cost while improving highly effective therapies.
    • 3.4. Market Trends
      • 3.4.1. The number of FDA approved cancer therapies continues to rise, with 63 cancer drugs launching within the past five years
      • 3.4.2. Over one-third of trials are using biomarkers to stratify patients, pointing to even more personalized cancer treatments in the future.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oncology Biosimilars, by Type, Application, Drug type, Cancer type, End user, Distribution channel and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Oncology Biosimilars (Value)
      • 5.2.1. Global Oncology Biosimilars by: Type (Value)
        • 5.2.1.1. G-CSF
        • 5.2.1.2. Hematopoietic Agents
        • 5.2.1.3. Monoclonal Antibodies
      • 5.2.2. Global Oncology Biosimilars by: Application (Value)
        • 5.2.2.1. Cancer Treatment Drugs
        • 5.2.2.2. Supportive Care Drugs
      • 5.2.3. Global Oncology Biosimilars by: Drug type (Value)
        • 5.2.3.1. Monoclonal antibody (mAb)
        • 5.2.3.2. Immunomodulators
        • 5.2.3.3. Hematopoietic agents
        • 5.2.3.4. G-CSF
        • 5.2.3.5. Others
      • 5.2.4. Global Oncology Biosimilars by: Cancer type (Value)
        • 5.2.4.1. Lung Cancer
        • 5.2.4.2. Colorectal cancer
        • 5.2.4.3. Cervical Cancer
        • 5.2.4.4. Breast Cancer
        • 5.2.4.5. Kidney cancer
        • 5.2.4.6. Stomach cancer
        • 5.2.4.7. Brain Cancer
        • 5.2.4.8. Others
      • 5.2.5. Global Oncology Biosimilars by: End user (Value)
        • 5.2.5.1. Retail Pharmacies
        • 5.2.5.2. Hospitals
      • 5.2.6. Global Oncology Biosimilars by: Distribution channel (Value)
        • 5.2.6.1. Hospital Pharmacies
        • 5.2.6.2. Online Pharmacies
        • 5.2.6.3. Retail Pharmacies
      • 5.2.7. Global Oncology Biosimilars Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Oncology Biosimilars (Price)
      • 5.3.1. Global Oncology Biosimilars by: Type (Price)
  • 6. Oncology Biosimilars: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biocon (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celltrion (South Korea)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dr Reddy laboratories (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F Hoffman-La Roche (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sandoz (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceuticals Ltd.(Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. STADA Arzneimittel AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BIOCAD (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sanofi (France)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Oncology Biosimilars Sale, by Type, Application, Drug type, Cancer type, End user, Distribution channel and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Oncology Biosimilars (Value)
      • 7.2.1. Global Oncology Biosimilars by: Type (Value)
        • 7.2.1.1. G-CSF
        • 7.2.1.2. Hematopoietic Agents
        • 7.2.1.3. Monoclonal Antibodies
      • 7.2.2. Global Oncology Biosimilars by: Application (Value)
        • 7.2.2.1. Cancer Treatment Drugs
        • 7.2.2.2. Supportive Care Drugs
      • 7.2.3. Global Oncology Biosimilars by: Drug type (Value)
        • 7.2.3.1. Monoclonal antibody (mAb)
        • 7.2.3.2. Immunomodulators
        • 7.2.3.3. Hematopoietic agents
        • 7.2.3.4. G-CSF
        • 7.2.3.5. Others
      • 7.2.4. Global Oncology Biosimilars by: Cancer type (Value)
        • 7.2.4.1. Lung Cancer
        • 7.2.4.2. Colorectal cancer
        • 7.2.4.3. Cervical Cancer
        • 7.2.4.4. Breast Cancer
        • 7.2.4.5. Kidney cancer
        • 7.2.4.6. Stomach cancer
        • 7.2.4.7. Brain Cancer
        • 7.2.4.8. Others
      • 7.2.5. Global Oncology Biosimilars by: End user (Value)
        • 7.2.5.1. Retail Pharmacies
        • 7.2.5.2. Hospitals
      • 7.2.6. Global Oncology Biosimilars by: Distribution channel (Value)
        • 7.2.6.1. Hospital Pharmacies
        • 7.2.6.2. Online Pharmacies
        • 7.2.6.3. Retail Pharmacies
      • 7.2.7. Global Oncology Biosimilars Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Oncology Biosimilars (Price)
      • 7.3.1. Global Oncology Biosimilars by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oncology Biosimilars: by Type(USD Million)
  • Table 2. Oncology Biosimilars G-CSF , by Region USD Million (2016-2021)
  • Table 3. Oncology Biosimilars Hematopoietic Agents , by Region USD Million (2016-2021)
  • Table 4. Oncology Biosimilars Monoclonal Antibodies , by Region USD Million (2016-2021)
  • Table 5. Oncology Biosimilars: by Application(USD Million)
  • Table 6. Oncology Biosimilars Cancer Treatment Drugs , by Region USD Million (2016-2021)
  • Table 7. Oncology Biosimilars Supportive Care Drugs , by Region USD Million (2016-2021)
  • Table 8. Oncology Biosimilars: by Drug type(USD Million)
  • Table 9. Oncology Biosimilars Monoclonal antibody (mAb) , by Region USD Million (2016-2021)
  • Table 10. Oncology Biosimilars Immunomodulators , by Region USD Million (2016-2021)
  • Table 11. Oncology Biosimilars Hematopoietic agents , by Region USD Million (2016-2021)
  • Table 12. Oncology Biosimilars G-CSF , by Region USD Million (2016-2021)
  • Table 13. Oncology Biosimilars Others , by Region USD Million (2016-2021)
  • Table 14. Oncology Biosimilars: by Cancer type(USD Million)
  • Table 15. Oncology Biosimilars Lung Cancer , by Region USD Million (2016-2021)
  • Table 16. Oncology Biosimilars Colorectal cancer , by Region USD Million (2016-2021)
  • Table 17. Oncology Biosimilars Cervical Cancer , by Region USD Million (2016-2021)
  • Table 18. Oncology Biosimilars Breast Cancer , by Region USD Million (2016-2021)
  • Table 19. Oncology Biosimilars Kidney cancer , by Region USD Million (2016-2021)
  • Table 20. Oncology Biosimilars Stomach cancer , by Region USD Million (2016-2021)
  • Table 21. Oncology Biosimilars Brain Cancer , by Region USD Million (2016-2021)
  • Table 22. Oncology Biosimilars Others , by Region USD Million (2016-2021)
  • Table 23. Oncology Biosimilars: by End user(USD Million)
  • Table 24. Oncology Biosimilars Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 25. Oncology Biosimilars Hospitals , by Region USD Million (2016-2021)
  • Table 26. Oncology Biosimilars: by Distribution channel(USD Million)
  • Table 27. Oncology Biosimilars Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 28. Oncology Biosimilars Online Pharmacies , by Region USD Million (2016-2021)
  • Table 29. Oncology Biosimilars Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 30. South America Oncology Biosimilars, by Country USD Million (2016-2021)
  • Table 31. South America Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 32. South America Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 33. South America Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 34. South America Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 35. South America Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 36. South America Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 37. Brazil Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 38. Brazil Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 39. Brazil Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 40. Brazil Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 41. Brazil Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 42. Brazil Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 43. Argentina Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 44. Argentina Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 45. Argentina Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 46. Argentina Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 47. Argentina Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 48. Argentina Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 49. Rest of South America Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 50. Rest of South America Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 51. Rest of South America Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 52. Rest of South America Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 53. Rest of South America Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 54. Rest of South America Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 55. Asia Pacific Oncology Biosimilars, by Country USD Million (2016-2021)
  • Table 56. Asia Pacific Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 57. Asia Pacific Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 58. Asia Pacific Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 59. Asia Pacific Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 60. Asia Pacific Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 61. Asia Pacific Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 62. China Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 63. China Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 64. China Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 65. China Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 66. China Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 67. China Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 68. Japan Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 69. Japan Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 70. Japan Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 71. Japan Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 72. Japan Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 73. Japan Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 74. India Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 75. India Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 76. India Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 77. India Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 78. India Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 79. India Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 80. South Korea Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 81. South Korea Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 82. South Korea Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 83. South Korea Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 84. South Korea Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 85. South Korea Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 86. Taiwan Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 87. Taiwan Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 88. Taiwan Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 89. Taiwan Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 90. Taiwan Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 91. Taiwan Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 92. Australia Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 93. Australia Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 94. Australia Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 95. Australia Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 96. Australia Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 97. Australia Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 98. Rest of Asia-Pacific Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 99. Rest of Asia-Pacific Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 100. Rest of Asia-Pacific Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 101. Rest of Asia-Pacific Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 102. Rest of Asia-Pacific Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 103. Rest of Asia-Pacific Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 104. Europe Oncology Biosimilars, by Country USD Million (2016-2021)
  • Table 105. Europe Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 106. Europe Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 107. Europe Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 108. Europe Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 109. Europe Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 110. Europe Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 111. Germany Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 112. Germany Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 113. Germany Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 114. Germany Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 115. Germany Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 116. Germany Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 117. France Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 118. France Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 119. France Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 120. France Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 121. France Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 122. France Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 123. Italy Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 124. Italy Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 125. Italy Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 126. Italy Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 127. Italy Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 128. Italy Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 129. United Kingdom Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 130. United Kingdom Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 131. United Kingdom Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 132. United Kingdom Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 133. United Kingdom Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 134. United Kingdom Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 135. Netherlands Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 136. Netherlands Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 137. Netherlands Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 138. Netherlands Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 139. Netherlands Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 140. Netherlands Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 141. Rest of Europe Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 142. Rest of Europe Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 143. Rest of Europe Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 144. Rest of Europe Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 145. Rest of Europe Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 146. Rest of Europe Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 147. MEA Oncology Biosimilars, by Country USD Million (2016-2021)
  • Table 148. MEA Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 149. MEA Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 150. MEA Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 151. MEA Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 152. MEA Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 153. MEA Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 154. Middle East Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 155. Middle East Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 156. Middle East Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 157. Middle East Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 158. Middle East Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 159. Middle East Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 160. Africa Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 161. Africa Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 162. Africa Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 163. Africa Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 164. Africa Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 165. Africa Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 166. North America Oncology Biosimilars, by Country USD Million (2016-2021)
  • Table 167. North America Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 168. North America Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 169. North America Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 170. North America Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 171. North America Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 172. North America Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 173. United States Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 174. United States Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 175. United States Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 176. United States Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 177. United States Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 178. United States Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 179. Canada Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 180. Canada Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 181. Canada Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 182. Canada Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 183. Canada Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 184. Canada Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 185. Mexico Oncology Biosimilars, by Type USD Million (2016-2021)
  • Table 186. Mexico Oncology Biosimilars, by Application USD Million (2016-2021)
  • Table 187. Mexico Oncology Biosimilars, by Drug type USD Million (2016-2021)
  • Table 188. Mexico Oncology Biosimilars, by Cancer type USD Million (2016-2021)
  • Table 189. Mexico Oncology Biosimilars, by End user USD Million (2016-2021)
  • Table 190. Mexico Oncology Biosimilars, by Distribution channel USD Million (2016-2021)
  • Table 191. Oncology Biosimilars: by Type(USD/Units)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Oncology Biosimilars: by Type(USD Million)
  • Table 204. Oncology Biosimilars G-CSF , by Region USD Million (2022-2027)
  • Table 205. Oncology Biosimilars Hematopoietic Agents , by Region USD Million (2022-2027)
  • Table 206. Oncology Biosimilars Monoclonal Antibodies , by Region USD Million (2022-2027)
  • Table 207. Oncology Biosimilars: by Application(USD Million)
  • Table 208. Oncology Biosimilars Cancer Treatment Drugs , by Region USD Million (2022-2027)
  • Table 209. Oncology Biosimilars Supportive Care Drugs , by Region USD Million (2022-2027)
  • Table 210. Oncology Biosimilars: by Drug type(USD Million)
  • Table 211. Oncology Biosimilars Monoclonal antibody (mAb) , by Region USD Million (2022-2027)
  • Table 212. Oncology Biosimilars Immunomodulators , by Region USD Million (2022-2027)
  • Table 213. Oncology Biosimilars Hematopoietic agents , by Region USD Million (2022-2027)
  • Table 214. Oncology Biosimilars G-CSF , by Region USD Million (2022-2027)
  • Table 215. Oncology Biosimilars Others , by Region USD Million (2022-2027)
  • Table 216. Oncology Biosimilars: by Cancer type(USD Million)
  • Table 217. Oncology Biosimilars Lung Cancer , by Region USD Million (2022-2027)
  • Table 218. Oncology Biosimilars Colorectal cancer , by Region USD Million (2022-2027)
  • Table 219. Oncology Biosimilars Cervical Cancer , by Region USD Million (2022-2027)
  • Table 220. Oncology Biosimilars Breast Cancer , by Region USD Million (2022-2027)
  • Table 221. Oncology Biosimilars Kidney cancer , by Region USD Million (2022-2027)
  • Table 222. Oncology Biosimilars Stomach cancer , by Region USD Million (2022-2027)
  • Table 223. Oncology Biosimilars Brain Cancer , by Region USD Million (2022-2027)
  • Table 224. Oncology Biosimilars Others , by Region USD Million (2022-2027)
  • Table 225. Oncology Biosimilars: by End user(USD Million)
  • Table 226. Oncology Biosimilars Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 227. Oncology Biosimilars Hospitals , by Region USD Million (2022-2027)
  • Table 228. Oncology Biosimilars: by Distribution channel(USD Million)
  • Table 229. Oncology Biosimilars Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 230. Oncology Biosimilars Online Pharmacies , by Region USD Million (2022-2027)
  • Table 231. Oncology Biosimilars Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 232. South America Oncology Biosimilars, by Country USD Million (2022-2027)
  • Table 233. South America Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 234. South America Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 235. South America Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 236. South America Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 237. South America Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 238. South America Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 239. Brazil Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 240. Brazil Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 241. Brazil Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 242. Brazil Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 243. Brazil Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 244. Brazil Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 245. Argentina Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 246. Argentina Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 247. Argentina Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 248. Argentina Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 249. Argentina Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 250. Argentina Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 251. Rest of South America Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 252. Rest of South America Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 253. Rest of South America Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 254. Rest of South America Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 255. Rest of South America Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 256. Rest of South America Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 257. Asia Pacific Oncology Biosimilars, by Country USD Million (2022-2027)
  • Table 258. Asia Pacific Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 259. Asia Pacific Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 260. Asia Pacific Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 261. Asia Pacific Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 262. Asia Pacific Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 263. Asia Pacific Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 264. China Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 265. China Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 266. China Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 267. China Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 268. China Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 269. China Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 270. Japan Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 271. Japan Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 272. Japan Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 273. Japan Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 274. Japan Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 275. Japan Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 276. India Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 277. India Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 278. India Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 279. India Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 280. India Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 281. India Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 282. South Korea Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 283. South Korea Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 284. South Korea Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 285. South Korea Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 286. South Korea Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 287. South Korea Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 288. Taiwan Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 289. Taiwan Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 290. Taiwan Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 291. Taiwan Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 292. Taiwan Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 293. Taiwan Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 294. Australia Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 295. Australia Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 296. Australia Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 297. Australia Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 298. Australia Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 299. Australia Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 300. Rest of Asia-Pacific Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 301. Rest of Asia-Pacific Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 302. Rest of Asia-Pacific Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 303. Rest of Asia-Pacific Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 304. Rest of Asia-Pacific Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 305. Rest of Asia-Pacific Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 306. Europe Oncology Biosimilars, by Country USD Million (2022-2027)
  • Table 307. Europe Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 308. Europe Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 309. Europe Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 310. Europe Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 311. Europe Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 312. Europe Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 313. Germany Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 314. Germany Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 315. Germany Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 316. Germany Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 317. Germany Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 318. Germany Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 319. France Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 320. France Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 321. France Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 322. France Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 323. France Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 324. France Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 325. Italy Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 326. Italy Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 327. Italy Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 328. Italy Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 329. Italy Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 330. Italy Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 331. United Kingdom Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 332. United Kingdom Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 333. United Kingdom Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 334. United Kingdom Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 335. United Kingdom Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 336. United Kingdom Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 337. Netherlands Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 338. Netherlands Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 339. Netherlands Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 340. Netherlands Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 341. Netherlands Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 342. Netherlands Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 343. Rest of Europe Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 344. Rest of Europe Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 345. Rest of Europe Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 346. Rest of Europe Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 347. Rest of Europe Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 348. Rest of Europe Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 349. MEA Oncology Biosimilars, by Country USD Million (2022-2027)
  • Table 350. MEA Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 351. MEA Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 352. MEA Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 353. MEA Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 354. MEA Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 355. MEA Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 356. Middle East Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 357. Middle East Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 358. Middle East Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 359. Middle East Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 360. Middle East Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 361. Middle East Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 362. Africa Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 363. Africa Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 364. Africa Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 365. Africa Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 366. Africa Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 367. Africa Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 368. North America Oncology Biosimilars, by Country USD Million (2022-2027)
  • Table 369. North America Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 370. North America Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 371. North America Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 372. North America Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 373. North America Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 374. North America Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 375. United States Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 376. United States Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 377. United States Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 378. United States Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 379. United States Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 380. United States Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 381. Canada Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 382. Canada Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 383. Canada Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 384. Canada Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 385. Canada Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 386. Canada Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 387. Mexico Oncology Biosimilars, by Type USD Million (2022-2027)
  • Table 388. Mexico Oncology Biosimilars, by Application USD Million (2022-2027)
  • Table 389. Mexico Oncology Biosimilars, by Drug type USD Million (2022-2027)
  • Table 390. Mexico Oncology Biosimilars, by Cancer type USD Million (2022-2027)
  • Table 391. Mexico Oncology Biosimilars, by End user USD Million (2022-2027)
  • Table 392. Mexico Oncology Biosimilars, by Distribution channel USD Million (2022-2027)
  • Table 393. Oncology Biosimilars: by Type(USD/Units)
  • Table 394. Research Programs/Design for This Report
  • Table 395. Key Data Information from Secondary Sources
  • Table 396. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oncology Biosimilars: by Type USD Million (2016-2021)
  • Figure 5. Global Oncology Biosimilars: by Application USD Million (2016-2021)
  • Figure 6. Global Oncology Biosimilars: by Drug type USD Million (2016-2021)
  • Figure 7. Global Oncology Biosimilars: by Cancer type USD Million (2016-2021)
  • Figure 8. Global Oncology Biosimilars: by End user USD Million (2016-2021)
  • Figure 9. Global Oncology Biosimilars: by Distribution channel USD Million (2016-2021)
  • Figure 10. South America Oncology Biosimilars Share (%), by Country
  • Figure 11. Asia Pacific Oncology Biosimilars Share (%), by Country
  • Figure 12. Europe Oncology Biosimilars Share (%), by Country
  • Figure 13. MEA Oncology Biosimilars Share (%), by Country
  • Figure 14. North America Oncology Biosimilars Share (%), by Country
  • Figure 15. Global Oncology Biosimilars: by Type USD/Units (2016-2021)
  • Figure 16. Global Oncology Biosimilars share by Players 2021 (%)
  • Figure 17. Global Oncology Biosimilars share by Players (Top 3) 2021(%)
  • Figure 18. Global Oncology Biosimilars share by Players (Top 5) 2021(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Biocon (India) Revenue, Net Income and Gross profit
  • Figure 21. Biocon (India) Revenue: by Geography 2021
  • Figure 22. Celltrion (South Korea) Revenue, Net Income and Gross profit
  • Figure 23. Celltrion (South Korea) Revenue: by Geography 2021
  • Figure 24. Dr Reddy laboratories (India) Revenue, Net Income and Gross profit
  • Figure 25. Dr Reddy laboratories (India) Revenue: by Geography 2021
  • Figure 26. F Hoffman-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. F Hoffman-La Roche (Switzerland) Revenue: by Geography 2021
  • Figure 28. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mylan (United States) Revenue: by Geography 2021
  • Figure 30. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Sandoz (Germany) Revenue: by Geography 2021
  • Figure 32. Teva Pharmaceuticals Ltd.(Israel) Revenue, Net Income and Gross profit
  • Figure 33. Teva Pharmaceuticals Ltd.(Israel) Revenue: by Geography 2021
  • Figure 34. STADA Arzneimittel AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. STADA Arzneimittel AG (Germany) Revenue: by Geography 2021
  • Figure 36. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 38. BIOCAD (United States) Revenue, Net Income and Gross profit
  • Figure 39. BIOCAD (United States) Revenue: by Geography 2021
  • Figure 40. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 41. Sanofi (France) Revenue: by Geography 2021
  • Figure 42. Global Oncology Biosimilars: by Type USD Million (2022-2027)
  • Figure 43. Global Oncology Biosimilars: by Application USD Million (2022-2027)
  • Figure 44. Global Oncology Biosimilars: by Drug type USD Million (2022-2027)
  • Figure 45. Global Oncology Biosimilars: by Cancer type USD Million (2022-2027)
  • Figure 46. Global Oncology Biosimilars: by End user USD Million (2022-2027)
  • Figure 47. Global Oncology Biosimilars: by Distribution channel USD Million (2022-2027)
  • Figure 48. South America Oncology Biosimilars Share (%), by Country
  • Figure 49. Asia Pacific Oncology Biosimilars Share (%), by Country
  • Figure 50. Europe Oncology Biosimilars Share (%), by Country
  • Figure 51. MEA Oncology Biosimilars Share (%), by Country
  • Figure 52. North America Oncology Biosimilars Share (%), by Country
  • Figure 53. Global Oncology Biosimilars: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Biocon (India)
  • Celltrion (South Korea)
  • Dr Reddy laboratories (India)
  • F Hoffman-La Roche (Switzerland)
  • Mylan (United States)
  • Sandoz (Germany)
  • Teva Pharmaceuticals Ltd.(Israel)
  • STADA Arzneimittel AG (Germany)
  • Pfizer Inc. (United States)
  • BIOCAD (United States)
  • Sanofi (France)
Additional players considered in the study are as follows:
AbbVie (United States) , Allergan (Ireland) , AstraZeneca (United Kingdom) , GalaxoSmitheKline (GSK) (United Kingdom) , Emcure Pharmaceuticals (India) , Intas Pharmaceuticals (India)
Select User Access Type

Key Highlights of Report


Apr 2022 249 Pages 60 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oncology Biosimilars Market Quantitative research analysis
Global Oncology Biosimilars Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Oncology Biosimilars market is expected to see a CAGR of % during projected year 2021 to 2027.
Top performing companies in the Global Oncology Biosimilars market are Biocon (India), Celltrion (South Korea), Dr Reddy laboratories (India), F Hoffman-La Roche (Switzerland), Mylan (United States), Sandoz (Germany), Teva Pharmaceuticals Ltd.(Israel), STADA Arzneimittel AG (Germany), Pfizer Inc. (United States), BIOCAD (United States) and Sanofi (France), to name a few.
North America is dominating the Oncology Biosimilars Market.

Know More About Global Oncology Biosimilars Market Report?

Have a Query? Click Here

Other Related Reports

Hepatitis C Drugs Comprehensive Study by Type (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), Application (Hospitals, Clinics), Disease (Acute Hepatitis C, Chronic Hepatitis C...
$ 3450
Human Vaccines Comprehensive Study by Type (Live-Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Toxoid Vaccines), Distribution Channel (Hospi...
$ 3450
Thin Film Drug Comprehensive Study by Type (Transdermal Film, Oral Thin Film), Application (Hospitals, Clinics, Others), Indication Type (Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting...
$ 3750
Infusion Pharmacy Management Comprehensive Study by Type (Antibiotics, Antimicrobial, Pain Management, Enteral Nutrition, Others), Application (Hospital & Clinic, Ambulatory Surgical Centers, Home Ca...
$ 3350
Active Pharma Ingredient Comprehensive Study by Type (Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients), Application (Oncology, Cardiovascular Disease, Diabetes...
$ 3750
Kinase Inhibitors Comprehensive Study by Type (Tyrosin Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors, Non-Receptor Tyrosine Kinase Inhibitors, Mulikinase Inhibitors, Threonine Kinase I...
$ 3750